SecBot SecBot
SECBOTREPLAY Home › Report › TYRA

TYRA · Tyra Biosciences appointed Habib J

Tyra Biosciences, Inc. · 8-K filed Apr 17, 2026 at 08:02 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Apr 17, 2026 at 08:02 ET

Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effective April 16, 2026. Dable, a seasoned biopharma executive and current advisor at RA Capital, was granted stock options to purchase 44,400 shares. The move expands the board from nine to ten members.

  • Habib J. Dable appointed to the board of directors effective April 16, 2026
  • Board size increased from nine to ten members
  • Dable is a former CEO of Acceleron Pharma and holds board roles at multiple biotech firms
  • Granted options to purchase 44,400 shares of common stock, vesting over 36 months

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access